FORTIS

Financial Highlights (as of FY 2025):

Financial Highlights (as of FY 2025): Revenue: ₹7,783 crore (consolidated). Net Income: ₹809 crore. Market Capitalization: Approximately ₹67,754 crore. P/E Ratio: High, around 78.01 times, which is a premium to the industry median. P/B Ratio: Around 7.38 times. Return on Equity (ROE): Poor, at 1.33% over the past three years. Debt/Equity: Approximately 0.20. Recent Developments and Outlook: Fortis Healthcare has been focusing on strategic initiatives, including brownfield expansions and acquisitions, to drive growth. Recent acquisitions include Medeor Hospital and Shrimann Superspecialty Hospital. The company's diagnostics business, Agilus Diagnostics, is a key growth driver. Fortis has been increasing its stake in the subsidiary. The company has faced historical legal and governance challenges related to its former promoters, which have been a point of attention for investors. Analysts currently have a "Strong Buy" consensus on the stock, with a forecast for continued earnings growth. Fortis Healthcare (India) Ltd. Fortis Healthcare Limited is a leading integrated healthcare service provider in India, founded in 1996. The company operates a network of hospitals, diagnostics centers (through its subsidiary Agilus Diagnostics), and daycare specialty facilities across India, the UAE, Nepal, and Sri Lanka. Fortis is listed on the BSE and NSE and is majority-owned by IHH Healthcare Berhad of Malaysia. Here is a summary of key financial and operational details for investors: Company Profile: Business: Operates multi-specialty and super-specialty hospitals, providing a full spectrum of integrated healthcare services. Presence: As of early 2025, the company has 36 healthcare facilities, approximately 4,000 operational beds, and over 400 diagnostics centers. Ownership: IHH Healthcare holds a significant stake (31.1%). Key Services: Specialties include cardiac care, oncology, orthopedics, neurosciences, and mother and child care.